Form 4: REGENXBIO Director Argeris N. Karabelas Reports Stock and Option Awards
SEC Form 4 Filing
Director Argeris N. Karabelas reports acquisition of REGENXBIO stock and options.
Summary
- On May 31, 2024, Argeris N. Karabelas, a director of REGENXBIO Inc., reported the acquisition of 4,790 shares of common stock and 24,454 stock options.
- The 4,790 shares represent a time-based restricted stock unit award (RSU) that will vest on May 1, 2025, contingent upon continued service.
- The stock options, with an exercise price of $14.35, will vest in 12 equal monthly installments starting May 31, 2024, also subject to continuous service.
- Following these transactions, Karabelas directly owns 11,286 shares of common stock and 24,454 stock options.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, and the sentiment is neutral. It reflects standard compensation practices.
Positives
- The granting of stock options and restricted stock units to a director aligns their interests with those of the shareholders.
- The vesting schedules tied to continued service incentivize the director to remain with the company.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Comparison to Industry Standards
- Stock option and RSU grants are common compensation practices for directors in publicly traded companies, particularly in the biotechnology sector.
- Vesting schedules tied to continued service are standard to ensure long-term commitment.
- The specific amounts and terms of the grants would need to be compared to peer companies to assess their relative generosity and alignment with performance.
Stakeholder Impact
- The stock and option awards align the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.
- Employees may view the grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 05/31/2024 | Date of transaction: acquisition of common stock and stock options. |
| 05/31/2024 | Options vest in 12 equal monthly installments following this date. |
| 05/31/2034 | Expiration date of the stock options. |
| 05/01/2025 | Date when the restricted stock units will vest. |
| 06/04/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.